Hemogenyx gets approval and issuance of European Hu-PHEC Patent

Hemogenyx Pharmaceuticals got European Patent Office’s patent entitled Post-Natal Hemogenic Endothelial Cells and their isolation and use.

If fully and successfully developed, the Hu-PHEC technology would provide a new form of blood stem cell replacement therapy and potentially eliminate the principal problems that arise from the existing forms of treatment, the company said.

Dr Vladislav Sandler, CEO & Co-founder of Hemogenyx, said: “The issue of the European patent is significant for the Company as it extends Hemogenyx’s commercial rights in Europe, thereby further solidifying and protecting Hemogenyx’s position as a leader in the area of cell therapy, and helping to place Hu-PHECs at the foundation of the development of novel methods of combatting blood cancers and auto-immune diseases.”